Marasco G, Colecchia A, Reggiani MLB, et al. - Researchers sought to assess the accuracy of the available prognostic models for hepatocellular carcinoma (HCC) to anticipate the survival of advanced HCC patients treated with Sorafenib included in the Italian Liver Cancer (ITA.LI.CA.) multicenter cohort. The performance of several prognostic scores was evaluated through a Cox regression-model assessing the C-index and the Akaike Information Criterion. Data from 1,129 patients were analyzed. Seven hundred eighty-nine patients died during a median follow-up period of 13 months. The CLIP score was the most reliable in predicting the overall survival of HCC patients treated with Sorafenib, although its efficiency remained low. Further studies are required to enhance the current ability to predict the outcome of HCC patients receiving Sorafenib.